Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Phase 2 N=16 Treatment of Liver Metastases With Electrochemotherapy
Liver Metastases
Primary: Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms) — 0; 0; 0 events
N/A N=6 Assess the Feasibility of Cone Beam CT to Localize Liver Metastases Immediately Prior to Radiotherapy
Localize Liver Metastases
Primary: Number of Participants Eligible for Cone Beam Tumor Localization" — 5 participants
Phase 2 N=23 Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II
Liver Metastases
Primary: Evaluation of Safety Related to Electrochemotherapy — 20; 3; 0; 0 Participants
N/A N=3 Stereotactic Body Radiation Therapy (SBRT) for Liver Mets
Liver Metastases
Primary: Maximum Tolerated Dose (MTD) — 60 Gy
N/A N=530 FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Colorectal Cancer · Colorectal Carcinoma · Liver Metastases
Primary: Progression-Free Survival (PFS) at Any Site — 10.7; 10.2 Months — p=0.551
Phase 3 N=209 FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Overall Survival (OS) — 25.9; 25.0 months — p=0.43
Phase 2 N=49 Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
Colorectal Cancer · Metastatic Cancer
Primary: 2 Year Disease-free Survival . — 9 percentage of participants
Phase 2 N=70 Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
Colon Cancer With Metastases to the Liver
Primary: Tumor Response — 31; 16 participants
Phase 2 N=151 TheraSphere for the Treatment of Liver Metastases
Colorectal Cancer · Carcinoma, Neuroendocrine · Neoplasm Metastasis
Primary: Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST) — 3.0; 17.9; 2.9; 3.4 Months
Phase 2 N=38 Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Metastatic Breast Cancer · Liver Metastases
Primary: Response Rate — 2; 13; 21; 1 Participants
N/A N=52 Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.
Colorectal Cancer
Primary: Complete Hepatic Response Rate at 3 Months — 79 percentage of participants
N/A N=4 TheraSphere® For Treatment of Metastases in Liver
Colorectal Cancer Metastatic · Colorectal Cancer
Primary: Number of Patients That Met the Criterion That the Dose Estimated With Tc-99m MAA SPECT Was Within 15% of the Dose Estimated From Y-90 SPECT — 4 Participants
Phase 2 N=50 Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Liver Cancer · Metastatic Cancer
Primary: Time to Progression — 2.3; 7.2 Months
Phase 2 N=58 Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Colorectal Cancer With Non Resectable Hepatic Metastasis
Primary: Progression-free Survival Rate at 9 Months — 30; 26 Participants
Phase 2 N=12 [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET — 0 Participants
Phase 2 N=3 Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
Liver Cancer · Liver Neoplasm · Hepatocellular Carcinoma
Primary: Number of Participants for Which Uptake of [18F]-FMISO Was Successful and Hypoxic Tumors Were Observed During PET Scan Imaging Post TACE Procedure — 0 Participants
Phase 2 N=50 Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Liver Neoplasms
Primary: Time to Progression (TTP) of the Treated Lesion(s) According to RECIST Criteria
Phase 2 N=64 PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Adult Hepatocellular Carcinoma · Localized Resectable Adult Liver Carcinoma
Primary: Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve…
Phase 2 N=14 Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Colorectal Cancer
Primary: Success of DEBIRI-M1 Procedure as a Measure of Feasibility (Percentage of Successful Treatments) — 100 percentage of successful treatments
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
N/A N=20 LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
Stage IV Melanoma
Primary: Incidence of Adverse Events — 465 Events
Phase 2 N=42 Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Colorectal Neoplasms · Neuroendocrine Tumors · Cholangiocarcinoma
Primary: Number of Participants With Adverse Events — 42 participants
Phase 2 N=30 Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Liver Cancer
Primary: Neovessel Formation as Measured by Angiogram at 14 Weeks — 2; 3 participants
N/A N=92 Individualized Stereotactic Body Radiotherapy of Liver Metastases
Solid Tumor · Liver Metastases
Primary: Local Control Rate — 77 percentage of participants
Phase 1 N=10 Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours
Liver Tumour
Primary: Concentration of Total Intratumoral Doxorubicin in Liver Tumour (Biopsies) Following Targeted Release of Doxorubicin From ThermoDox® ('Drug') Using Mild Hyperthermia…
Phase 2 N=16 Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
Liver Metastases · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity — 0; 0; 1 participants with DLTs
Phase 2 N=39 Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Liver Cancer
Primary: Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) — 1; 1; 17; 15 Participants
Phase 2 N=9 Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
Liver Cancer · Pancreatic Cancer
Primary: Median Overall Survival (OS) — 14.09 months